




RealRate

PHARMACEUTICAL 2016

International Stem Cell CORP
Rank 228 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 18% points. The greatest weakness of International Stem Cell CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 213% points.

The company's Economic Capital Ratio, given in the ranking table, is 154%, being 109% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	2,991
Cost of Goods Sold	2,056
Intangible Assets	3,223
Liabilities, Current	5,544
Liabilities, Non-Current	0
Other Assets	549
Other Compr. Net Income	0
Other Expenses	2,637
Other Liabilities	0
Other Net Income	1,929
Other Revenues	7,551
Property and Equipment	375
Research and Development	2,707
Selling, General and Administrative Expense	4,715

Output Variable	Value in 1000 USD
Assets	7,138
Liabilities	5,544
Expenses	12,115
Revenues	7,551
Stockholders Equity	1,594
Net Income	-2,635
Comprehensive Net Income	-2,635
BaseVar	17,138
ECR before Limited Liability	13%
Economic Capital Ratio	154%